Moderna's COVID-19 Vaccine Candidate To Enter Phase 3 Trial

Moderna's preliminary vaccine trials showed promising results, with all 45 participants developing antibodies against COVID-19. The trial involved administering the vaccine twice at varying dosages, with higher dosages yielding stronger antibodies. Side effects were mild, including pain at the injection site, headache, chills, and muscle pain. Unlike traditional vaccines, Moderna's uses mRNA to trigger an immune response. The vaccine may offer protection for up to two years. Phase three of the trial is set to begin on July 27th with 30,000 participants.

What was the outcome for all participants in Moderna's initial vaccine trial?

• They all developed antibodies.

• They all showed no response to the vaccine.

• They all experienced severe side effects.

• They all required hospitalization.

How does the strength of antibodies relate to the dosage in Moderna's trial?

• Higher dosages resulted in weaker antibodies.

• Lower dosages resulted in stronger antibodies.

• Higher dosages resulted in stronger antibodies.

• Dosage had no effect on antibody strength.

What is unique about Moderna's vaccine compared to most traditional vaccines?

• It is administered orally.

• It requires only one dose.

• It uses mRNA to trigger an immune response.

• It uses a live virus.

What is the reported duration of protection offered by Moderna's vaccine?

• Up to one year

• Up to five years

• Up to six months

• Up to two years

When is Moderna's phase three trial scheduled to begin?

• August 1st

• July 27th

• September 10th

• June 15th